

Rev07
Update: Aug,20,2025

DATASHEET

Anti-Ipilimumab Antibody (4H6), mAb, Mouse

Cat. No.: A01961

Overview

Specificity	The product is specific for Ipilimumab. The antibody is recommended as a detection antibody in a pharmacokinetic (PK) bridging assay with capture antibody GenScript, A01859-40, Anti- Ipilimumab Antibody (26B6H7D9), mAb, Mouse.
Host Species	Mouse
Immunogen	Ipilimumab
Conjugate	Unconjugated

Applications

Working concentrations for specific applications should be determined by the investigators. The appropriate concentrations may be affected by secondary antibody affinity, antigen concentration, the sensitivity of the method of detection, temperature, the length of the incubations, and other factors. The suitability of this antibody for applications other than those listed below has not been determined. The following concentration ranges are recommended starting points for this product.


Application	Recommended Usage
ELISA	0.01-0.1 µg/ml

Properties

Form	Lyophilized
Storage Buffer	lyophilized with PBS, pH 7.4, containing 0.02% sodium azide.
Reconstitution	Reconstitute the lyophilized powder with deionized water (or equivalent) to an final concentration of 0.5 mg/mL.
Storage Instructions	The lyophilized product remains stable for 1 year at -20°C from the date of receipt. Upon reconstitution, it can be stored for 2-3 weeks at 2-8°C or for 12 months at -20°C or below. Avoid freeze/thaw cycles.
Purification	Protein A affinity column
Isotype	Mouse IgG1
Clonality	Monoclonal

Clone ID	4H6
Note	GenScript can customize this product per customer's request including product size, buffer components, etc.

Examples



Anti-Ipilimumab Antibody (4H6), mAb, Mouse (GenScript, A01961-40) binds with Ipilimumab, while the antibody does not recognize human IgG Fc fragment (data not shown).
Coating antigen: Ipilimumab, 1 µg/ml.
Anti-Ipilimumab antibody dilution start from 1,000 ng/ml.

Background

Target Background : Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells. Anti-Ipilimumab Antibody (4H6), mAb, Mouse is produced from a hybridoma resulting from the fusion of partner and B-lymphocytes obtained from a mouse immunized with Ipilimumab.

Synonyms : Mouse monoclonal to Yervoy

For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.

Manufacturer: Nanjing GenScript Biotech Co., Ltd. No. 28Yongxi Road, Jiangning District, Nanjing, Jiangsu, China